Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?

Abstract

Macrolide monotherapy is currently recommended as first-line treatment of mild-to-moderate community-acquired pneumonia (CAP) in penicillin-intolerant/allergic individuals in the UK. However, resistance rates among the commonest cause, Streptococcus pneumoniae, now exceed 10% in the UK and a review of alternative agents is therefore timely. This review considers the relative merits of two agents, doxycycline and moxifloxacin, which are candidates to replace macrolides for second-line therapy of non-severe CAP.

• Authors: H A Ludlam, D A Enoch
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 32 Issue 2 Pg. 101-5 (Aug 2008) ISSN: 0924-8579 [Print] Netherlands
• PMID: 18571380 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Aza Compounds
• Fluoroquinolones
• Quinolines
• Doxycycline
• Moxifloxacin

Topics

• Anti-Bacterial Agents (therapeutic use)
• Aza Compounds (therapeutic use)
• Clinical Trials as Topic
• Community-Acquired Infections (drug therapy, microbiology)
• Doxycycline (therapeutic use)
• Fluoroquinolones
• Humans
• Moxifloxacin
• Pneumonia, Bacterial (drug therapy, microbiology)
• Quinolines (therapeutic use)
• Treatment Outcome
• United Kingdom